Article Text

other Versions

PDF
Consensus Statement on the Use of Rituximab in Patients With Rheumatoid Arthritis
  1. Josef S Smolen (josef.smolen{at}wienkav.at)
  1. Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    1. Paul Emery (p.emery{at}leeds.ac.uk)
    1. Dept of Rheumatology, United Kingdom
      1. Edward C Keystone (ksnow{at}mtsinai.on.ca)
      1. University of Toronto, Canada
        1. Ferry Breedveld (f.c.breedveld{at}lumc.nl)
        1. University Hospital Leiden, Netherlands
          1. Neil Betteridge (neilb{at}arthritiscare.org)
          1. Arthritis Care, London, United Kingdom
            1. Gerd Burmester (gerd.burmester{at}charite.de)
            1. Charite University Hospital, Germany
              1. Maxime Dougados (m.doug{at}cch.aphp.fr)
              1. Hopital Cochin, Paris, France
                1. GF Ferraccioli (gf.ferraccioli{at}rm.unicatt.it)
                1. Postgraduate School in Rheumatology, Italy
                  1. Ulrich Jaeger (eulrich.jaeger{at}meduniwien.ac.at)
                  1. Medical University of Vienna, Austria
                    1. Lars Klareskog (lars.klareskog{at}medks.ki.se)
                    1. Karolinska Hospital, Sweden
                      1. Tore K Kvien (t.k.kvien{at}ioks.uio.no)
                      1. Diakonhjemmet Hospital, Norway
                        1. Emilio Martin-Mola (emartinmola{at}infonegocio.com)
                        1. Hospital La Paz, Uruguay
                          1. Karel Pavelka (pavelka{at}revma.cz)
                          1. Na slupi 4, Czech Republic

                            Abstract

                            A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B-cell targeted therapy with rituximab in RA. Underlying the statement were data from randomised controlled clinical trials and the vast literature in oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in RA.

                            • Rheumatoid arthritis
                            • Rituximab
                            • anti-B-cell
                            • anti-TNF failure
                            • therapy

                            Statistics from Altmetric.com

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.